Pulmatrix (PULM) vs Xenetic Biosciences (XBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulmatrix is the larger company by market cap ($5.6 million vs $5.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PULM | XBIO |
|---|---|---|
| Share price | $1.53 | $2.12 |
| Market cap | $5.58M | $4.97M |
| 1-day change | +2.49% | -4.07% |
| EPS (TTM) | $-1.10 | $-1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.24 | $8.87 |
| 52-week low | $1.16 | $1.87 |
| Distance from 52-week high | -70.83% | -76.10% |
| Average volume | 24.09K | 87.31K |
| Shares outstanding | 3.65M | 2.34M |
| Employees | 2 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Healthcare · Biotechnology · 2 employees
About Xenetic Biosciences
XBIO stock →Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance.
Healthcare · Biotechnology · 2 employees
PULM vs XBIO FAQ
Which is bigger, Pulmatrix or Xenetic Biosciences?
Pulmatrix (PULM) is larger, with a market capitalization of $5.58M compared with $4.97M for Xenetic Biosciences (XBIO).
Are Pulmatrix and Xenetic Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.